Results 71 to 80 of about 15,728 (206)

Impact of CYP2C19 and CYP3A4 Inhibitor Use on Clopidogrel Clinical Effectiveness in CYP2C19 Genotyped Patients Undergoing Percutaneous Coronary Intervention

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 531-541, August 2026.
CYP2C19 and CYP3A4 contribute to clopidogrel bioactivation. CYP2C19 no‐function alleles diminish clopidogrel's antiplatelet effects and clinical effectiveness. Coadministration of either a CYP2C19 or a CYP3A4 inhibitor may also reduce clopidogrel's antiplatelet effects and lead to phenoconversion in patients without a CYP2C19 no‐function allele (normal/
Danwei Shao, Jean G. Malavé, Joseph S. Rossi, Francesco Franchi, Ellen C. Keeley, Dominick J. Angiolillo, George A. Stouffer, Larisa H. Cavallari, Craig R. Lee   +8 more
wiley   +1 more source

Prasugrel for the treatment of patients with acute coronary syndrome

Vascular Health and Risk Management, 2009
Filippo Marzot, Vittorio PengoClinical Cardiology, Thrombosis Centre, University of Padua, ItalyAbstract: Prasugrel (CS-747, LY640315) is a novel member of the thienopyridine class of oral anti-platelet agents (also including ticlopidine and clopidogrel).
Filippo Marzot, Vittorio Pengo
doaj  

Modern Antiplatelet Therapy for Percutaneous Coronary Intervention. How to Make the Right Choice?

Рациональная фармакотерапия в кардиологии, 2020
Dual antiplatelet therapy is the most important step in acute coronary syndrome (ACS) treatment. The new generation of inhibitors of P2Y12 platelet receptors (prasugrel and ticagrelor) provide more pronounced platelet inhibition than clopidogrel.
T. M. Uskach, A. S. Tereshchenko
doaj   +1 more source

Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry

European Journal of Preventive Cardiology, 2020
Introduction The benefits of short versus long-term dual antiplatelet therapy (DAPT) based on the third generation P2Y12 antagonists prasugrel or ticagrelor, in patients with acute coronary syndromes treated with percutaneous coronary intervention remain
F. D’Ascenzo, M. Bertaina, F. Fioravanti, F. Bongiovanni, S. Raposeiras-Roubín, E. Abu-Assi, T. Kinnaird, A. Ariza-Solé, S. Manzano-Fernández, C. Templin, L. Velicki, I. Xanthopoulou, E. Cerrato, A. Rognoni, G. Boccuzzi, P. Omede', Andrea Montabone, S. Taha, A. Durante, S. Gili, G. Magnani, M. Autelli, A. Grosso, P. F. Blanco, A. Garay, G. Quadri, F. Varbella, B. C. Queija, R. C. Paz, M. C. Fernández, I. M. Pousa, D. Gallo, U. Morbiducci, A. Domínguez-Rodríguez, M. Valdés, Á. Cequier, D. Alexopoulos, A. Iñíguez-Romo, F. Gaita, M. Rinaldi, T. Lüscher   +40 more
semanticscholar   +1 more source

Influence of the Residual Gensini Score on Prognosis of Patients With ST‐Elevation Myocardial Infarction

Catheterization and Cardiovascular Interventions, Volume 108, Issue 1, Page 76-83, July 1, 2026.
ABSTRACT Background The residual Gensini score (rGS) was developed to quantify the severity of coronary atheroma burden after coronary revascularisation. The predictive value of the rGS for clinical outcomes in patients with ST‐segment elevation myocardial infarction (STEMI) remains unexplored.
Batric Popovic, Nassima Djaballah, Mirela Tomic, Renaud Fay, Victorine Fraichot, Florian Eggenspieler, Pierre Adrien Metzdorf, Jeanne Varlot, Edoardo Camenzind   +8 more
wiley   +1 more source

High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel.

PLoS ONE, 2015
BackgroundPrasugrel is more effective than clopidogrel in reducing platelet aggregation in acute coronary syndromes. Data available on prasugrel reloading in clopidogrel treated patients with high residual platelet reactivity (HRPR) i.e. poor responders,
Tobias Geisler, Jean Booth, Elli Tavlaki, Athanasios Karathanos, Karin Müller, Michal Droppa, Meinrad Gawaz, Monica Yanez-Lopez, Simon J Davidson, Rod H Stables, Winston Banya, Azfar Zaman, Marcus Flather, Miles Dalby, Miles Dalby   +14 more
doaj   +1 more source

Feasibility and Safety of Distal Transradial Access in Patients With Out‐of‐Hospital Cardiac Arrest Undergoing Emergency PCI: A Single‐Center Retrospective Study

Catheterization and Cardiovascular Interventions, Volume 108, Issue 1, Page 269-274, July 1, 2026.
ABSTRACT Background Distal transradial access (dTRA) has gained attention for its lower risk of vascular complications compared to conventional transradial access (TRA). However, its feasibility and safety in patients with out‐of‐hospital cardiac arrest (OHCA) undergoing emergency percutaneous coronary intervention (PCI) remain uncertain.
Shiori Kawakami, Norimasa Taniguchi, Takeshi Yamada, Tetsuya Hata, Shunsuke Nakajima, Fumihiko Sano, Hideya Nakano, Mitusko Yokouchi, Aiko Ko, Akihiko Takahashi   +9 more
wiley   +1 more source

P2Y₁₂ Receptor Inhibitors in the Treatment of Patients with Acute Coronary Syndrome and Percutaneous Coronary Intervention: Possibilities of Prasugrel

Рациональная фармакотерапия в кардиологии, 2019
The possibilities of P2Y12 receptor inhibitors application in the treatment of patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) are discussed in the article.
N. M. Vorobyeva
doaj   +1 more source

Prior Myocardial Infarction and Treatment Effect of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndromes ‐ A Post‐hoc Analysis of the ISAR‐REACT 5 Trial

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Background The efficacy and safety of ticagrelor versus prasugrel in patients with acute coronary syndrome and prior myocardial infarction (MI) remain unstudied. We aimed to assess the treatment effect of ticagrelor versus prasugrel according to prior MI
Shqipdona Lahu, Maria Scalamogna, Gjin Ndrepepa, Maurizio Menichelli, Christian Valina, Rayyan Hemetsberger, Bernhard Witzenbichler, Isabell Bernlochner, Michael Joner, Erion Xhepa, Alexander Hapfelmeier, Sebastian Kufner, Hendrik B. Sager, Katharina Mayer, Thorsten Kessler, Karl‐Ludwig Laugwitz, Gert Richardt, Heribert Schunkert, Franz‐Josef Neumann, Adnan Kastrati, Salvatore Cassese   +20 more
doaj   +1 more source

Spontaneous Coronary Reperfusion in STEMI After Pre‐Hospital Loading Dose of Triple Antithrombotic Therapy

Clinical Cardiology, Volume 49, Issue 7, July 2026.
ABSTRACT Background To evaluate the incidence and prognosis of spontaneous coronary reperfusion in STEMI using pre‐hospital loading dose of P2Y12 inhibitors. Methods This prospective bi‐centric study included STEMI patients who referred for primary PCI from June 1, to November 1, 2022.
Pierre Alain Meunier, Lea Juenin, Lionel Moulis, François Roubille, Pierre Robert, Jean Christophe Macia, Jean‐Michel Berdeu, Matthieu Steinecker, Benoit Lattuca, Laurent Schmutz, Luc Cornillet, Guillaume Cayla, Florence Leclercq   +12 more
wiley   +1 more source